Eif2B2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | EIF2B2 |
|---|---|
| Full Name | Eukaryotic Translation Initiation Factor 2B Subunit Beta |
| Chromosomal Location | 14q24.3 |
| NCBI Gene ID | 9479 |
| OMIM | 606454 |
| Ensembl ID | ENSG00000148377 |
| UniProt ID | P49407 |
| Associated Diseases | Vanishing White Matter Disease, Leukoencephalopathy |
EIF2B2 (Eukaryotic Translation Initiation Factor 2B Subunit Beta) is a critical gene encoding one of the five subunits of eIF2B, the guanine nucleotide exchange factor that recycles eIF2-GDP to eIF2-GTP. This process is essential for translational initiation in all eukaryotic cells.
EIF2B2 mutations are associated with vanishing white matter disease (VWM), an autosomal recessive leukoencephalopathy. The gene is ubiquitously expressed with high levels in brain white matter.
EIF2B2 encodes the beta subunit of eukaryotic translation initiation factor 2B (eIF2B), which functions as the guanine nucleotide exchange factor (GEF) for eIF2. The eIF2B complex is essential for translational initiation as it catalyzes the exchange of GDP for GTP on eIF2, enabling the formation of the ternary complex required for start codon recognition[1].
The eIF2B heterodecamer consists of two copies of each of five subunits (alpha, beta, gamma, delta, epsilon). The beta subunit contributes to the structural integrity and regulatory function of the complex. eIF2B is a key regulator of the integrated stress response (ISR), where phosphorylation of eIF2alpha leads to competitive inhibition of eIF2B, reducing global translation while promoting expression of stress-response genes[2].
Mutations in EIF2B2 are a common cause of vanishing white matter disease (VWM), an autosomal recessive leukodystrophy characterized by progressive neurological deterioration, cerebellar ataxia, and spasticity. The disease typically presents in childhood but can also manifest in adolescence or adulthood. Neuropathologically, VWM is characterized by cystic degeneration and disappearance of cerebral white matter[3].
Pathogenic variants in EIF2B2 reduce eIF2B activity, compromising the cell's ability to respond to various stresses. This is particularly detrimental to oligodendrocytes and astrocytes, which require robust stress response mechanisms for myelin maintenance and homeostatic support[4].
EIF2B2 is ubiquitously expressed with highest levels in the brain, especially in white matter regions. Within the central nervous system, the protein is expressed in oligodendrocytes, astrocytes, and neurons. Its localization in the cytoplasm facilitates its role in translational regulation[5].
The study of Eif2B2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.